Nomogram to Predict Cognitive Impairment in Patients with Asymptomatic Middle Cerebral Artery Stenosis

Purpose This study aims to investigate the characteristics and influencing factors of cognitive impairment in patients with asymptomatic middle cerebral artery stenosis (aMCAS) and to construct a nomogram to predict the risk of cognitive impairment in patients with aMCAS. Patients and Methods We collected 54 patients with aMCAS and 35 healthy controls to investigate the impaired cognitive domains and pathogenesis in patients with aMCAS. All patients underwent a cranial MRI, CT perfusion, transcranial Doppler ultrasound, blood tests, and a comprehensive neuropsychological evaluation. According to the MoCA score, patients were divided into cognitively normal and cognitively impaired groups. To construct the nomogram, we conducted univariate and multivariate logistic regression analyses to identify factors that affect cognitive function. And the performance of nomogram was evaluated by ROC curves, calibration curves, decision curve analysis (DCA), and clinical impact curve (CIC). Results In 54 patients with aMCAS, 24 patients presented with cognitive normal, and 30 patients presented with cognitive impairment. The results of multivariate logistic regression suggested that perfusion decompensation, middle cerebral artery mean flow velocity, and LDL-cholesterol levels were independent influencing factors of cognitive impairment. In the following step, a nomogram was constructed. The AUC of the nomogram is 0.862. Calibrating curves show good agreement between nomogram predictions and actual observations, while DCA and CIC show great clinical usefulness. Conclusion Patients with aMCAS have cognitive impairment in multiple cognitive domains, and impaired executive function was observed during the perfusion compensation period. Furthermore, a nomogram was constructed and validated to predict the risk of cognitive impairment in patients with aMCAS, which can help clinicians to identify at an early stage and improve the management of patients.

[1]  T. Krings,et al.  Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial. , 2022, JAMA.

[2]  Jiansong Fang,et al.  Connecting the Dots Between Hypercholesterolemia and Alzheimer’s Disease: A Potential Mechanism Based on 27-Hydroxycholesterol , 2022, Frontiers in Neuroscience.

[3]  Jianfeng Luo,et al.  Relation of middle cerebral artery flow velocity and risk of cognitive decline: A prospective community-based study , 2022, Journal of Clinical Neuroscience.

[4]  Rong Wang,et al.  Altered functional connectivity is related to impaired cognition in left unilateral asymptomatic carotid artery stenosis patients , 2021, BMC Neurology.

[5]  M. Silvestrini,et al.  Impact of carotid stenosis on cerebral hemodynamic failure and cognitive impairment progression: a narrative review , 2021, Annals of translational medicine.

[6]  Baoliang Zhong,et al.  Low levels of low-density lipoprotein cholesterol and cognitive decline. , 2021, Science bulletin.

[7]  R. Marshall,et al.  Cognitive Impairment Correlates Linearly with Mean Flow Velocity by Transcranial Doppler below a Definable Threshold , 2020, Cerebrovascular Diseases Extra.

[8]  Tao Wang,et al.  Longitudinal and nonlinear relations of dietary and Serum cholesterol in midlife with cognitive decline: results from EMCOA study , 2019, Molecular Neurodegeneration.

[9]  Yingchun Liu,et al.  Cognitive Decline in Asymptomatic Middle Cerebral Artery Stenosis Patients with Moderate and Poor Collaterals: A 2-Year Follow-Up Study , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[10]  H. Chu,et al.  Cognitive impairment and intracranial atherosclerotic stenosis in general population , 2018, Neurology.

[11]  J. Coresh,et al.  Association of midlife lipids with 20-year cognitive change: A cohort study , 2018, Alzheimer's & Dementia.

[12]  R. Kalaria,et al.  Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementia. , 2017, Clinical science.

[13]  S. Kimura,et al.  Does cerebral large-artery disease contribute to cognitive impairment? , 2017, eNeurologicalSci.

[14]  G. Assmann,et al.  Can LDL cholesterol be too low? Possible risks of extremely low levels , 2017, Journal of internal medicine.

[15]  S. Kwon,et al.  Intracranial Artery Stenting May Not Improve Cognitive Function: A Preliminary Study , 2016, Journal of stroke.

[16]  G. Pergola,et al.  Associative Learning Beyond the Medial Temporal Lobe: Many Actors on the Memory Stage , 2013, Front. Behav. Neurosci..

[17]  J. Pickard,et al.  Transcranial Doppler Pulsatility Index: What it is and What it Isn’t , 2012, Neurocritical Care.

[18]  Juliana Ben,et al.  Chronic brain hypoperfusion causes early glial activation and neuronal death, and subsequent long-term memory impairment , 2012, Brain Research Bulletin.

[19]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[20]  Wenzhen Zhu,et al.  Glial gap junctional communication involvement in hippocampal damage after middle cerebral artery occlusion , 2011, Annals of neurology.

[21]  R. O’Connell,et al.  The Molecular Genetics of Executive Function: Role of Monoamine System Genes , 2011, Biological Psychiatry.

[22]  V. Demarin,et al.  Assessment of subtle cognitive impairment in stroke-free patients with carotid disease. , 2009, Acta clinica Croatica.

[23]  P. Wolf,et al.  Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. , 2009, Stroke.

[24]  Jia Liu,et al.  Decreased cerebral blood flow velocity in apolipoprotein E ɛ4 allele carriers with mild cognitive impairment , 2007 .

[25]  S. Black,et al.  National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards , 2006, Stroke.

[26]  L. V. van Doornen,et al.  Does carotid endarterectomy improve cognitive functioning? , 2005, Journal of vascular surgery.

[27]  M. Eriksson,et al.  Patients with atherosclerosis may have increased circulating levels of 27‐hydroxycholesterol and cholestenoic acid , 2005, Scandinavian journal of clinical and laboratory investigation.

[28]  O. Witte,et al.  Delayed neuronal death and damage of GDNF family receptors in CA1 following focal cerebral ischemia , 2004, Brain Research.

[29]  Steve Meaney,et al.  Brain Cholesterol: Long Secret Life Behind a Barrier , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[30]  O. Joakimsen,et al.  Reduced neuropsychological test performance in asymptomatic carotid stenosis , 2004, Neurology.

[31]  F. Pfrieger,et al.  Cholesterol homeostasis and function in neurons of the central nervous system , 2003, Cellular and Molecular Life Sciences CMLS.

[32]  B. Pappas,et al.  Brain blood flow restoration ‘rescues’ chronically damaged rat CA1 neurons , 1993, Brain Research.

[33]  J. Arenillas,et al.  Intracranial atherosclerosis: current concepts. , 2011, Stroke.

[34]  J. Zhou,et al.  Decreased cerebral blood flow velocity in apolipoprotein E epsilon4 allele carriers with mild cognitive impairment. , 2007, European journal of neurology.